Cancer, Costs and Compulsion: Kerala High Court Opens the Section 100 Patents Act Door
In In Re Exorbitant Pricing of Life Saving Patented Medicines, the Kerala High Court asked whether the Section 100 Patents Act lets the Union of India make and…
Eli Lilly
4 articles
After Natco, Bajaj Healthcare files compulsory license against Eli Lilly; EPO Enlarged Board of Appeal issues decision on ‘double patenting’ and more
Bajaj Healthcare has applied for a compulsory license against Eli Lilly for Baricitinib, citing affordability concerns. The post also covers the EPO's decision on double patenting, updates from…
Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more
Natco Pharma has withdrawn its compulsory license application for Baricitinib following an agreement with Eli Lilly. The Indian Patent Office has extended procedural deadlines, and other significant updates…
Patent Infringement Claim on Cancer Treatment Drug
The UK Court of Appeal ruled that Actavis’s alternative salt forms of pemetrexed would indirectly infringe Eli Lilly’s cancer drug patent. The decision provides insights into patent claim…